BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Company executives will be holding a conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008 following the release of third quarter 2008 financial results and to review preliminary data from CuraGen's Phase II clinical trial evaluating CR011-vcMMAE for the treatment of advanced melanoma.
Data from CuraGen's Phase II trial of CR011-vcMMAE will be presented during an oral session at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer (iSBTc), being held October 31 - November 2, 2008, in San Diego, CA. The results will be presented on Saturday, November 1, 2008, at 3:15 p.m. Pacific time in the Tumor Targeting Monoclonal Antibodies session.
Press releases detailing the financial results and the Phase II data on CR011-vcMMAE will be issued prior to market open on Monday, November 3, 2008.
A replay of the conference call and webcast will be available beginning at 2:00 p.m. ET on Monday, November 3, 2008 through Wednesday, December 3, 2008 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 71190212. An archive of the webcast will also be available for 30 days at http://www.curagen.com.
About CuraGen
CuraGen Corporation is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.
CONTACT: Sean Cassidy, Vice President and Chief Financial Officer,
+1-203-871-4400, scassidy@curagen.com, or Glenn Schulman, PharmD, Director
of Medical Communications, +1-888-436-6642, gschulman@curagen.com, both of
CuraGen Corporation
Web site: http://www.curagen.com/
